AMAZE 2: Amycretin Phase 3 trial (NCT07533175)
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Recruiting
- Enrolment
- 630
- estimated
- Start
- 13 Apr 2026 (actual)
- Primary completion
- 7 Aug 2028 (estimated)
- Sponsor
- Novo Nordisk A/S
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| NNC0487-0111 dose level 1 | Experimental | Drug: NNC0487-0111 | Participants will be randomized to receive NNC0487-0111 dose level 1 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity. |
| NNC0487-0111 dose level 2 | Experimental | Drug: NNC0487-0111 | Participants will be randomized to receive NNC0487-0111 dose level 2 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity. |
| NNC0487-0111 dose level 3 | Experimental | Drug: NNC0487-0111 | Participants will be randomized to receive NNC0487-0111 dose level 3 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity. |
| NNC0487-0111 dose level 4 | Experimental | Drug: NNC0487-0111 | Participants will be randomized to receive NNC0487-0111 dose level 4 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity. |
| Placebo | Placebo comparator | Drug: Placebo (matched to NNC0487-0111) | Participants will receive placebo matched to NNC0487-0111 subcutaneously once weekly as an adjunct to a reduced-calorie diet and increased physical activity. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Relative change in body weight | From baseline (week 0) to (week 84) |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change in waist circumference | From baseline (week 0) to (week 84) |
| Change in glycated haemoglobin (HbA1c) | From baseline (week 0) to (week 84) |
| Change in systolic blood pressure (SBP) | From baseline (week 0) to (week 84) |
| Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) physical function score | From baseline (week 0) to (week 84) |
| Change in SF-36v2® Health Survey Acute (SF-36v2 Acute) physical functioning score | From baseline (week 0) to (week 84) |
| Change in body weight | From baseline (week 0) to (week 84) |
| Change in body mass index (BMI) | From baseline (week 0) to (week 84) |
| Change in IWQOL-Lite-CT: Physical, Psychosocial, Total score | From baseline (week 0) to (week 84) |
| Achievement of HbA1c < 7.0% (Yes/No) | From baseline (week 0) to (week 84) |
| Achievement of HbA1c ≤ 6.5% (Yes/No) | From baseline (week 0) to (week 84) |
| Achievement of HbA1c < 5.7% (Yes/No) | From baseline (week 0) to (week 84) |
| Change in fasting plasma glucose (FPG) (mmol/L) | From baseline (week 0) to (week 84) |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.